| 1. | Jarrard DF, Blute ML, Ritter MA. Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J. Clin. Oncol. 2014 Dec 10; 32(35):3926-9. [PubMed ID: 25332250] |
|---|---|
| 2. | Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.Nat Rev Urol 2014 Oct; 11(10):589-96. [PubMed ID: 25245244] |
| 3. | Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur. Urol. 2014 Dec; 66(6):1139-47. [PubMed ID: 25194909] |
| 4. | Richards KA, Negron E, Cohn JA, Steinberg Z, Eggener SE, Shalhav AL. The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J. Endourol. 2014 Nov; 28(11):1338-44. [PubMed ID: 24935823, PMCID: 4382827] |
| 5. | Large MC, Malik R, Cohn JA, Richards KA, Ganshert C, Kunnavakkum R, Smith ND, Steinberg GD. Prospective health-related quality of life analysis for patients undergoing radical cystectomy and urinary diversion. Urology 2014 Oct; 84(4):808-13. [PubMed ID: 25109565] |
| 6. | Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZ. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol. Oncol. 2015 Feb; 33(2):70.e1-7. [PubMed ID: 25044254] |
| 7. | Cowan NG, Chen Y, Downs TM, Bochner BH, Apolo AB, Porter MP, La Rochelle JC, Amling CL, Koppie TM. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol 2014; 2014():746298. [PubMed ID: 24982672, PMCID: 4058463] |
| 8. | Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. J. Urol. 2014 Oct; 192(4):1050-6. [PubMed ID: 24704115] |
| 9. | Abel EJ, Wong K, Sado M, Leverson GE, Patel SR, Downs TM, Jarrard DF. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS 2014 Apr-Jun; 18(2):282-7. [PubMed ID: 24960494, PMCID: 4035641] |
| 10. | Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 2013 Dec; 73(16):1721-30. [PubMed ID: 23999928, PMCID: 4237278] |
| 11. | Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 2013 Apr; 15(4):399-408. [PubMed ID: 23555185, PMCID: 3612912] |
| 12. | Slezak J, Truong M, Huang W, Jarrard D. HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. BMC Cancer 2013 Mar 23; 13():148. [PubMed ID: 23522301, PMCID: 3618256] |
| 13. | Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate 2013 Jun; 73(9):970-8. [PubMed ID: 23335089, PMCID: 3755376] |
| Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J. Urol. 2013 Feb; 189(2):422-9. [PubMed ID: 23017522, PMCID: 3581046] |
